Ayala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend Its Reporting Obligations

GlobeNewswire05/10 04:10

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

GlobeNewswire03/26 20:00

Ayala Completes Patient Enrollment for Pivotal Desmoid Tumor Study

Investing.com 02/20 23:32

Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

GlobeNewswire02/20 21:00

Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating

MT Newswires02/07 21:53

Immunome Shares Rise 16% After Acquisition of Potential Tumor Treatment From Ayala Pharmaceuticals

WSJ02/06 23:53